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Abstract Splenic marginal zone lymphoma (SMZL) is a
low-grade lymphoma showing a rather nonspecific immuno-
phenotype. Gene expression profiling studies suggested that
TCL1A could be a marker of SMZL, but reported data are
conflicting. We evaluated TCL1A expression in a series of
spleen and bone marrow samples involved by SMZL and
correlated the findings with other immunophenotypical, mor-
phological, and clinical data. In addition, we evaluated the
expression of TCL1A in a series of spleens and lymph nodes
involved by lymphomas that might mimic SMZL (13 nodal
marginal zone lymphomas (NMZL), 39 follicular lymphomas
(FL), 30 B-cell chronic lymphocytic leukemias (B-CLL), 31
mantle cell lymphomas (MCL), 1 lymphoplasmacytic lym-
phoma) and 15 bone marrow specimens involving hairy cell
leukemia (HCL). TCL1A staining was negative in 24/31 cases
of SMZL (77%); 27/31MCL and all B-CLLwere positive for
TCL1A; 32/34 cases of nodal FL (96 %) and all five splenic
FL were positive for TCL1A, although at a lower intensity.
Eight of 13 NMZLwere positive for TCL1A, often showing a
heterogeneous staining pattern. All HCL samples were strong-
ly positive for TCL1A. No correlation was found between the
pattern of splenic infiltration, TCL1A expression, and the
clinical course. TCL1A-positive SMZL showed a higher rate
of DBA44 staining compared to the negative ones, and this
difference was statistically significant (Fisher test, single-
tailed, p00.0397). Our data support the use of TCL1A in the
panel of diagnostic markers used in the differential diagnosis
of splenic low-grade B-cell lymphoma; a possible prognostic
value, however, needs a larger series to be established.
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Introduction
Splenic B-cell marginal zone lymphoma is a rare entity, ac-
counting for less than 2 % of all lymphoid malignancies; it
shows an indolent clinical course, although 10 % of cases
progress to diffuse large B cell lymphoma [1]. The diagnosis
of SMZL relies on a combination of histopathological analysis
and immunophenotyping of the spleen samples, although
bone marrow biopsies are frequently the first and often the
only sample analyzed by pathologists, since splenectomy is
not clinically required in a large percentage of patients [2].
A commercially available specific marker of SMZL is
lacking, and the immunophenotypical profile of SMZL
is currently mainly defined on the basis on the lack of
expression of markers associated with its mimickers
(follicular lymphoma, mantle cell lymphoma, B-cell
chronic lymphocytic leukemia/small lymphocytic lym-
phoma, hairy cell leukemia), including CD5, CD10,
CD23, cyclin D1, CD25, CD11c, and Annexin A1 to
name just a few. However, both SMZL and its mimick-
ers can occasionally show an aberrant phenotype (e.g.,
expression of CD5 and/or CD23 in SMZL or lack of
CD10 in follicular lymphomas (FL)), making a final
diagnostic decision more difficult. The detection of the
deletion of 7q might help, because it is rare in other
lymphoma subtypes, while it is present in about 30–
40 % of SMZL [3, 4]; its detection, however, might be
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impractical for routine testing and is not completely
specific. So far, the only reliable marker of marginal zone
differentiation is IRTA-1 [5–7], but the antibody is not com-
mercially available. Differentiating SMZL from other lympho-
mas is even more problematic in bone marrow biopsies, where
neoplastic cells can be scarce, morphologic criteria are less
solid, the immunophenotype might differ, and genetic analysis
might not work. Myeloid cell nuclear differentiation antigen
(MNDA) has recently been described as a sensitive (although
not completely specific) marker of nodal and splenic marginal
zone lymphomas, that might be useful both in primary sites and
in the bone marrow [8].
Although not widely used, TCL1A is a helpful marker in
lymphoma characterization [9]. TCL1A (T-cell leukemia/
lymphoma 1A) is a proto-oncogene member of a multigene
family that includes TCL1B and MTCP1 [10]. TCL1A maps
to the 14q32.1 locus and has been shown to enhance the
activity of the Akt kinase, which plays a central role in
regulating cellular survival [11, 12]. In T-cell prolympho-
cytic leukemia, TCL1A acts like a classic oncogene through
constitutive activation [13]. The oncogenic role of TCL1A
in B-cell malignancies is less well understood: while in
murine models it appears to retain a major function in the
development of B-cell tumors [14], in humans, such a role is
less clear.
Herling et al. reported the expression of TCL1A in a
high percentage of precursor B acute lymphoblastic
leukemia/lymphoblastic lymphoma, Burkitt lymphoma,
and mantle cell lymphoma, while FL showed positive
staining in 57 % of cases [9]. Leich et al. correlated
TCL1A expression with the presence of the t(14;18)
translocation in FL, with 84 % of translocation-
positive cases showing TCL1A expression, while 80 %
of t(14;18)-negative FL without BCL2 protein expres-
sion were also TCL1A negative [15]. These data sup-
port the hypothesis that TCL1A expression is down-
regulated in B-cell tumors resembling a late B-cell
program.
The present literature reports conflicting data regarding
the expression of TCL1A in SMZL. Herling and co-workers
[9] reported a small series of ten SMZL, which were all
negative for TCL1A; variable expression of TCL1A mRNA
was instead reported by Aggarwal et al. [16]. In a series
published by Ruiz-Ballesteros et al., the protein appears to
be expressed by immunohistochemistry in 80 % of cases
(14/20) [17].
In this study, we analyzed the expression of TCL1A in a
series of 31 consecutive cases of SMZL, which to our
knowledge is the largest series so far; for 25 patients,
matched bone marrow biopsies were available. Morpholog-
ical, immunophenotypical, and clinical data were collected
and correlated. Our data support the use of TCL1A in the
diagnostic workup for SMZL.
Methods
Cases
Thirty-one consecutive cases of SMZL were retrieved from
the archives of the Department of Pathology and Diagnostics,
University of Verona. For 25 cases, one or more matched bone
marrow biopsies were available.
Clinical data were available for 24 SMZL cases and included
age at diagnosis, gender, spleen size, presence of autoimmune
phenomena, hemoglobin, white cell count, presence of neoplas-
tic circulating cells, presence of M component, albumin and
LDH values, HBVand HCV serology, liver and nodal involve-
ment, overall survival (OS), and disease-free survival (DFS).
Nine cases of non-Hodgkin lymphoma involving the
spleen were used as controls, including five follicular lym-
phomas (FL), one mantle cell lymphoma (MCL), one small B-
cell lymphoma/chronic lymphocytic leukemia (B-CLL/SLL),
one hairy cell leukemia (HCL), and one lymphoplasmacytic
lymphoma (LPL). Five normal spleen specimens (removed
after traumatic injury) were also included in the study.We also
added a series of lymph node cases involving lymphomas that
might mimic SMZL (13 NMZL, 34 FL, 29 B-CLL/SLL, 30
MCL) and 15 bone marrow specimens involving hairy cell
leukemia, which might be a differential diagnostic problem
when only minimal involvement is present.
Morphological classification
Cases were classified morphologically as described by Isaacson
et al. [18]. Spleen specimens were divided into three groups
according to the main pattern of neoplastic infiltration: “nodu-
lar” (white pulp effaced by tumor cells with scant red pulp
infiltration), “nodular/diffuse” (marked expansion of tumor
cells with variable nodular/intrasinusoidal involvement of the
red pulp), and “primarily diffuse” (white pulp completely ef-
faced with massive red pulp involvement) [18–20]. In bone
marrow biopsies, the neoplastic infiltrate was defined as “sinu-
soidal” (rows of at least three to four cells positive for B-cell
markers inside sinusoids), “interstitial” (small and discohesive
groups of cells dispersed in the bone marrow interstitium), and
“nodular pattern” (neoplastic cells organized in nodules that
may be associated with an interstitial and/or sinusoidal
component).
Construction of tissue microarrays
Three tissue microarrays were built using a manual arrayer
(Beecher Instruments). After morphological evaluation and
marking of proper areas in H&E-stained slides, three 2-mm
cores were taken from each block. All slides were scanned
using the D-SIGHT device (Menarini Diagnostics, Florence,
Italy).
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Immunohistochemistry
Immunohistochemical staining was performed using an autos-
tainer (Leica BondMax) using the following antibodies: CD5,
CD20, Ki67, cyclin D1, CD123, TCL1, T-bet, DBA44,
BCL2, BCL6, CD23, ANXA1, MNDA, and GCET1
(Table 1). MNDA and GCET1 antibodies were kindly
provided by Dr. Roncador (CNIO, Madrid, Spain). Dou-
ble staining was performed as previously described [21].
Statistical analysis




Clinical data were available for 24 cases. Mean age was
62 years (range 48–79). All cases presented with spleno-
megaly (spleen mean main axis 22 cm, range 15–30) and all
underwent splenectomy for diagnostic and therapeutic pur-
poses. Fourteen of 24 cases (58 %) presented with liver
enlargement and 17/24 with lymphadenopathy. In all
patients with an available bone marrow trephine biopsy, an
involvement was demonstrated.
Other relevant findings were lymphocytosis (11/24
patients, 45 %), anemia (7/24, 29 %), thrombocytopenia (14/
24, 58 %), presence of serum M component (10/24, 41 %),
and autoimmune phenomena (8/24, 33%); 2/24 (8%) patients
resulted HCV positive and other two (8 %) HBV positive.
One third of patients (8/24, 33 %) presented an IPI score of 3–
4, while 15/24 (62 %) an IPI score of 1–2; data were not
available for one case. Seven of 24 (29 %) presented LDH
values above normal range; 3/24 (12 %) presented an albumin
concentration below 35 g/L. Sixteen of 24 patients (66 %) had
normal values of albumin, LDH, and hemoglobin; 3/24
patients (12 %) had one of these three values outside the
normal range, 3/24 patients (12 %) had two abnormal values,
and 2/24 (8%) had all three values outside the reference range.
As a first line of therapy, 9/24 (37 %) patients were treated
with chemotherapy, consisting of alkylating agents with or
without rituximab besides splenectomy; the remaining 15
patients underwent splenectomy alone. Of these, 11 under-
went chemotherapy as second-line therapy. The mean follow-
up period was 69months (range 6–233). During the follow-up
period, 5/24 patients (20 %) died because of the lymphoma,
after a mean period of 80 months (range 49–110); 9/24 (37 %)
patients presented signs of disease progression. At the time of
the last clinical observation, 7/24 patients (29 %) were free
from disease after chemotherapy/splenectomy.
Morphological classification
In the spleen, a nodular pattern of infiltration was present in 8/
31 cases (26 %), a nodular/diffuse pattern in 15/31 cases
(48 %), and a primarily diffuse pattern in 8/31 cases (26 %).
In bone marrow biopsies, we found a mixed nodular/intersti-
tial/sinusoidal pattern in 9/25 cases (36 %), nodular/sinusoidal
in 5/25 (20 %), interstitial/sinusoidal in 4/25 (16 %), nodular/
interstitial in 1/25 (4 %), purely sinusoidal in 3/25 (12 %), and
purely interstitial in 3/25 (12 %) (Table 2). We detected a
secretive differentiation in 4/31 cases (13 %); neoplastic in-
volvement of the liver was documented in 13/31 cases (42 %).
Immunohistochemistry
Normal spleen (Fig. 1a, CD20 staining depicted in Fig. 1b)
showed the typical targetoid staining for TCL1A (Fig. 1c),
with germinal center cells stained at intermediate intensity,
mantle cells strongly stained, and marginal zone cells un-
stained. MNDA, as previously described, stained both man-
tle and marginal zone cells (Fig. 1d).
In SMZL (Fig. 2a, CD20 staining depicted in Fig. 2b),
TCL1A staining was negative in 24/31 cases (77 %)
(Fig. 2c); MNDA was positive in 29/31 cases (94 %)
(Fig. 2d). In the bonemarrow (Fig. 3a, CD20 staining depicted
in Fig. 3b), TCL1A staining was negative in 21/25 cases
(84 %) (Fig. 3c); MNDAwas positive in 22/25 cases (88 %)
(Fig. 3d). Out of the five cases that were positive for TCL1A
on spleen specimens and were paired with bone marrow
biopsies, four resulted positive for TCL1A also in the bone
marrow biopsy (for two cases with spleen samples bone
marrow biopsies were not available). In the bone marrow,
MNDAwas also positive in myeloid cells, thus requiring the
Table 1 Antibodies used in the study
Antigen Clone Producer Dilution
CD5 4C7 Labvision 1:150
CD20 L26 Dako 1:250
Ki67 MM1 Novocastra 1:50
TCL1A 27D6/20 MBL 1:500
T-bet 4B10 Santa Cruz 1:100
CCND1 SP4 Neomarkers 1:10
CD123 7 G3 BD 1:100
DBA44 DBA44 Dako 1:20
BCL2 124 Dako 1:40
BCL6 LN22 Novocastra 1:10
CD23 1B12 Novocastra 1:100
ANXA1 B01P Abnova 1:100
MNDA 235 CNIO Pure supernatant
GCET1 RAM341 Abcam/CNIO 1:500
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use of double staining forMNDA and CD20 to correctly score
B cells.
Thirteen of 30 (43 %) cases showed a variable degree of
staining for DBA44, although only 5/30 (17 %) in more than
35 % of cells. Five of the six TCL1A-postive cases where
also DBA44 positive (83 %), while 8/24 TCL1A-negative
cases showed expression of DBA44 (33 %). This difference
was not statistically significant using a two-sided Fisher
exact test (p00.0606) but became significant when using a
single-tailed test (p00.0397). T-bet resulted positive in 7/31
cases (22 %), while ANXA1, cyclin D1, and CD123 were
invariably negative. In one case, the neoplastic cells were
CD5 positive, but negative for CD23, cyclin D1, and
TCL1A; thus, a splenic localization of CLL/SLL or MCL
was reasonably excluded. TCL1A-positive cases showed no
apparent peculiarities when compared to the negative ones;
the staining was present usually only in part of the cells (36–
75 % in six of seven cases) and with variable intensity
(Fig. 4a).
Among lymph node cases involved by lymphomas that
might mimic SMZL, 8/13 (61 %) of NMZL showed a
positive but heterogeneous staining with a “mosaic-like”
Table 2 Synopsis of histopathological and immunohistochemical results
Case Splenic pattern Bone marrow pattern CD5 CD20 Ki67 TCL1A MNDA T-
bet
DBA44 Bcl2 Bcl6
Spleen BM Spleen BM
2 N NIS − +++ − − − + + w − − ++ −
4 N NA − ++ − − NA + NA − − + −
14 N NA − +++ − − NA + NA − − ++ −
28 N IS − +++ − − − + + w − − +++ −
30 N IS − +++ − − − ++ + NA − ++ −
1 ND NS − ++ − − − + + w − − − −
6 ND NS − ++ − − − ++ + w − − + −
11 ND I − +++ ++ − − ++ + w − − +++ −
21 ND S − +++ − − − + + w − − +++ +
23 ND NIS − +++ − − − + + w ++ − +++ +
26 ND NIS − +++ + − − + + w − − ++ −
27 ND NS − +++ − − − + + w − − +++ −
29 ND NIS − +++ + ++ + − − NA − ++ −
31 D NA − +++ − ++ NA + NA +++ NA ++ NA
5 D NIS − ++ − − − + − − − + −
16 D NS − +++ − − − ++ + w − − +++ −
17 D S − +++ − − − + + w − − ++ −
25 D NA − ++ − − NA + NA + − + −
20 D NIS − +++ − − − + + w − + ++ −
12 D S − +++ − − − + + w − ++ +++ −
9 D I − +++ ++ ++ − + + w +++ +++ ++ −
15 ND NIS − +++ − − − + + w − + +++ −
18 ND NI − ++ − − − − − ++ + ++ −
13 ND IS − +++ − ++ + + + w − + +++ −
10 ND NA − +++ − +++ NA + NA − + +++ −
7 ND NA − +++ − − NA + NA − ++ ++ −
22 ND I − +++ − − − + + +++ ++ + +
24 ND IS − +++ − − − + + w +++ +++ − +
19 N NS − ++ − − − + + − + +++ −
3 N NIS − +++ − ++ + w + + w − + ++ −
8 N NIS + +++ − ++ + + + w − ++ ++ −
Cases ordered by pattern and DBA44 staining. Case numbers according to chronological order. Splenic pattern of infiltration: N nodular, ND
nodular/diffuse, D diffuse. Bone marrow pattern of infiltration: N nodular, I interstitial, S sinusoidal. Immunostain evaluation, percentage of
positive cells: −, <10 %; +, 11–35 %; ++, 36–75 %; +++, >75 %; NA not available, w weak, BM bone marrow
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pattern (Fig. 4b). Twenty-seven of 30 MCL as well as all
CLL/SLL (29/29) stained strongly and diffusely for TCL1A
(three MCL cases showed a weak or heterogeneous staining
that was scored as negative), while 32/34 cases of FL (94 %)
were positive for TCL1A. All HCL bone marrow trephine
biopsies (15/15) were positive for TCL1A. All spleen
Fig. 1 Normal spleen parenchyma. a Normal spleen parenchyma, H&E (×10); b CD20 (×10); c TCL1A highlights mantle cells and scattered germinal
center cells but results negative in marginal zone cells (×10); dMNDA (×10)
Fig. 2 Spenic marginal zone B-cell lymphoma, nodular and diffuse pattern of infiltration. aH&E (×10); bCD20 (×10); c TCL1A results negative in the
neoplastic cells (×10); dMNDA results positive in the neoplastic component (×10)
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samples involved by other lymphoma/leukemia subtypes
(five FL, one B-CLL, one MCL, one HCL, one LPL) stained
positive for TCL1A.
Clinicopathological correlation
No correlation was found between the type of splenic infil-
tration and the clinical course, including OS and DFS. We
did not find any statistically significant correlation between
TCL1A expression and the primarily diffuse pattern seen in
7/31 cases, nor with disease progression. In fact, we did not
find any difference in terms of TCL1A expression among
cases with a diffuse pattern of splenic infiltration compared
to those with a nodular or nodular and diffuse pattern.
Discussion
Due to the lack of specific markers, splenic marginal zone
B-cell lymphoma is still a diagnosis of exclusion. The use of
a large number of markers, even negative, allows exclusion
of morphologically similar entities and thus improves diag-
nostic reliability. The problem is more pertinent when ana-
lyzing bone marrow specimens, since the diagnostic criteria
are less reliable, and morphological evaluation is sometimes
of limited help. Since only a part of the patients with SMZL
Fig. 3 Bone marrow involvement by splenic marginal zone B-cell lymphoma showing a prevalently interstitial pattern of infiltration. a H&E (×20); b
CD20 (×20); c TCL1A (×20); d: MNDA (×20)
a 
b 
Fig. 4 Examples of TCL1A-positive cases of splenic and nodal mar-
ginal zone lymphoma. a Example of a TCL1A-positive splenic mar-
ginal zone lymphoma (×10); b example of a TCL1A-positive nodal
marginal zone lymphoma (×10); a residual non-neoplastic germinal
center is also present
682 Virchows Arch (2012) 461:677–685
undergo splenectomy before a bone marrow biopsy is taken,
these specimens are often the first (and frequently the only)
samples available for evaluation.
In this paper, we analyzed the expression of TCL1A in
SMZL, a marker that is lost in marginal zone differentiation
of normal B cells [9], the mRNA of which was detected at
high levels in SMZL [22] although current literature is
conflicting regarding its expression as detected by immuno-
histochemistry. In addition, we analyzed matched spleen
and bone marrow samples and described the morphological
and immunohistochemical findings in both. We also ana-
lyzed possible correlations with clinical parameters such as
disease progression, albumin, hemoglobin, and LDH values.
Our series of cases showed an indolent course and good
prognosis, similar to previously published studies. Only 5/
24 patients (21 %) for whom clinical data were available
died because of lymphoma, after a median interval of
80 months (range 49–110). Nine of 24 patients (37 %)
underwent disease progression, three of whom developed
transformation to diffuse large B-cell lymphoma.
Morphologically, a purely diffuse pattern was present in 8/
31 (26 %) of spleen samples of SMZL, while the majority
showed a classical nodular pattern with or without red pulp
involvement. Three of the purely diffuse cases were also
positive for DBA44 and, based on the 2008 WHO criteria,
would fit in the provisional category called “splenic B-cell
lymphoma, unclassifiable,” which includes a subcategory
called splenic diffuse red pulp lymphoma. DBA44 was not
restricted to the purely diffuse subtypes, however, since also
ten other cases with mixed or nodular patterns showed a
variable degree of expression (Table 2). Moreover, four cases
with a purely diffuse pattern were DBA44 negative, support-
ing the view that this marker might not be strictly associated
with a diffuse pattern of infiltration. A recent series of splenic
diffuse red pulp lymphomas, however, included also cases
which were DBA44 negative [23]. Interestingly, we found a
higher rate of expression of DBA44 in TCL1A-positive cases,
since five of the six (83 %) TCL1A-positive cases where also
DBA44 positive, while 8/24 (33 %) TCL1A-negative cases
showed expression of DBA44 to some extent. This associa-
tion was not statistically significant using a two-tailed Fisher
test (p00.0606). Since we wanted to test the positive associ-
ation between TCL1A and DBA44, a one-tailed test might be
appropriate which turned out to be significant (p00.0397).
The small number of cases did not allow a more powerful
statistical approach, but the high prevalence of double-
positive cases is intriguing and warrants further investigation
of the hypothesis that DBA44-positive cases might be differ-
ent from the negative ones, irrespective of the growth pattern.
On the bone marrow biopsies, we confirmed what was
reported so far in the literature [24] concerning the presence
of a sinusoidal pattern of infiltration, which we observed (often
associated with nodular and interstitial aggregates) in 80 % of
cases. Regarding other immunophenotypic markers, all cases
were negative for CD10, CD23, CD123, cyclin D1, and
ANXA1. CD5 appeared positive in one case only, which was
negative for CD23 and CCND1 excluding other entities such as
MCL and B-CLL.
In our series, TCL1Awas negative in almost 80% of cases of
SMZL. This finding is at variancewith the high levels ofmRNA
of TCL1A detected in another series [22]. Several explanations
are possible for this curious phenomenon, including low trans-
lation rate of mRNA and fast protein degradation. The reported
positive staining in 80 % of SMZL [17] is more difficult to
explain, also considering variations in the techniques used.
The absence of TCL1A staining seems a useful feature in
defining SMZL: while in fact only 7/31 (22 %) of cases of
SMZL showed positive staining for TCL1A, among cases of
lymphomas that might mimic SMZL, 8/13 (61 %) of NMZL
showed a mosaic-like, heterogeneously positive staining, while
all nodal B-CLL/SLL (29/29) and 27/30 (90 %) nodal MCL
showed strong and diffuse positivity for TCL1A (the remaining
three MCL cases showed a weak or heterogeneous staining).
Moreover, 32/34 nodal cases of FL (94 %) and all HCL bone
marrow trephine biopsy (15/15) stained positive for TCL1A. In
the spleen, five FL, one MCL, one B-CLL/SLL, one HCL, and
one LPL also showed expression of TCL1A.
As previously said, among the five cases that were positive
for TCL1A on spleen specimens and had paired bone marrow
biopsies, one case was negative in the bone marrow biopsy.
This asymmetry might be due to the interaction between
neoplastic cells with the bone marrow microenvironment or
simply to a lower technical performance on de-calcified sam-
ples (however, a few positive cells were always detectable).
In a study conducted in 2006 by Herling et al. [25], the
expression of TCL1 has been evaluated on a series of 213 cases
of CLL/SLL; in 90 % of the cases, expression of TCL1 was
found by flow cytometry, immunohistochemistry, and western
blotting. The highest level of expression obtained was lower
than that observed in T-cell prolymphocytic leukemia (T-PLL),
but correlated with expression of ZAP-70 and presence of wild-
type IGHV genes. In splenic marginal zone B-cell lymphomas,
this latter correlation has never been directly proven, but indi-
rect evidence comes from studies that demonstrated that the
presence of wild-type IGHV genes correlates with the presence
of deletion of 7q31 [26] and that such a deletion correlates in
turn with the expression of TCL1A in SMZL [17]. Further
studies are therefore needed to verify this hypothesis.
In a multicenter study conducted by the Intergruppo Ital-
iano Linfomi, Arcaini et al. [27] suggested, on a large series of
consecutively diagnosed SMZL (309 cases), three parameters
predictive for a shorter survival: hemoglobin less than 120 g/
L, albumin less than 35 g/L, and LDH above normal values.
These authors proposed a prognostic model which considers
three groups: in particular, low risk (no adverse factors),
intermediate risk (one adverse factor), and high risk (two or
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three parameters out of normal range). We did not find any
correlation between the high risk group and the expression of
TCL1A, although a statistically significant correlation
(p<0.05) is present if the three abnormal parameters are taken
together and correlated with TCL1A-positive staining.
TCL1A expression might therefore be a predictor of shorter
survival, but the low number of TCL1A-positive cases does
not allow a powerful statistical analysis.
Recently, Kanellis et al. [8] evaluated the expression
of MNDA in a broad spectrum of lymphoid neoplasias,
reporting that all of the 20 cases of SMZL tested were
positive for this marker. In our series, we found this
antigen expressed in 94 % of cases. We can confirm
the usefulness of this marker, with the caveat of a strong
expression in myeloid cells that might impair the recog-
nition of the MNDA-positive lymphoid infiltrate, espe-
cially in the interstitial pattern of infiltration. In our
opinion, the use of a double staining procedure, using a
membrane/cytoplasmic B-cell marker such as CD20,
greatly facilitates the evaluation of MNDA. Interestingly,
one of the two splenic MNDA-negative cases was
DBA44 positive, and the other was TCL1A positive;
moreover, one case that was MNDA negative only in
the bone marrow showed a diffuse pattern in the spleen.
In consideration of these data and of those concerning
DBA44 previously discussed, we propose to investigate
the hypothesis that aberrant phenotypic/morphologic fea-
tures tend to cluster together. We hypothesize that besides
classical SMZL and the relatively well-described “diffuse
red pulp lymphoma,” there might be a third group dis-
playing a classical (i.e., nonpurely diffuse) pattern but
showing an aberrant phenotype. The clinical and biolog-
ical significance of this group, however, needs to be
investigated on a larger series and possibly using high-
throughput technologies to identify specific molecular
signatures. In conclusion, our data support the use of
TCL1A in the panel of diagnostic markers used in the
differential diagnosis of splenic low-grade B-cell lympho-
ma; a possible biological and/or prognostic significance
of this marker and the possible existence of a novel
group of splenic lymphomas with an aberrant phenotype,
however, need evaluation of a larger series.
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